INTRODUCTION
The pathologic hallmarks of Parkinson's disease (PD), which was originally described by James Parkinson in 1817, are a loss of dopamine (DA) neurons and the formation of Lewy bodies (LBs) in the remaining neuronal cytoplasm in the substantia nigra. [1] [2] [3] [4] [5] The clinical features of PD consist of resting tremor, cogwheel rigidity, bradykinesia and loss of postural reflex. Although the age of onset in the sporadic PD is usually older, recent reports have described a young and/or juvenile age of onset in several cases of parkinsonism. PD is always sporadic (about 95%), and only a few patients are familial PD or parkinsonism. Parkinsonian symptoms are found in many disorders, such as autosomal recessive juvenile parkinsonism (AR-JP), hereditary progressive dystonia {HPD, also known as L-dihydroxyphenylalanine (L-DOPA)-responsive dystonia (DRD) or Segawa's disease}, frontotemporal dementia and parkinsonism linked to chromosome 17 , dementia with LB {DLB, also known as diffuse LB disease (DLBD)}, pure akinesia, multiple system atrophy (including striatonigral degeneration, sporadic olivopontocerebellar atrophy and Shy-Drager syndrome), progressive supranuclear palsy, structural lesions (due to infarct, tumor, or hydrocephalus), brain injury (including encephalitis or punch-drunk encephalopathy), treatment with multiple drugs (to block D 2 -receptors), poisoning by carbon monoxide or manganese, etc., suggesting that parkinsonism can have many causes. [1] [2] [3] [4] [5] Mutations in several genes have also been identified as possible causes, such as mutations in the asynuclein, 6, 7) parkin, 8) tau, 9) ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1), 10) and GTP cyclohydrolase 1 (GCH-1) 11) genes (Table 1 ).
Other as yet unidentified genes have also been linked to chromosomes 2P and 4P. 3, 5) Thus, since many pathogenic factors are involved in parkinsonian symptoms, the sensitivity or responsiveness to L-DOPA (levodopa), which is the standard antiparkinsonian drug, varies within each parkinsonism (Table 1) .
DA SYNTHESIS AND DA RECEPTORS
DA is produced by several synthetic enzymes, such as tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC, also known as L-DOPA decarboxylase) (Fig. 1) . TH activity requires the cofactor tetrahydrobiopterin (BH 4 ), which is produced by GCH-1, 6-pyruvoyl tetrahydropterin synthase (PTPS) and sepiapterin reductase (SPR) (Fig. 1 ). Human HPD/DRD patients, who exhibit juvenileonset dystonia without a loss of DA neurons, often show mutations in the GCH-1 gene. 11) Since such patients only lack BH 4 synthesis and have lower TH activity, they respond to L-DOPA without its side-effects. DA is further metabolized to noradrenaline and adrenaline by dopamine b-hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT), respectively. Therefore, DA neurons lack these enzymes. Nurr1, an orphan nuclear receptor, plays an essential role in the differentiation of DA neurons. 12) Recent gene-targeting and transgenic strategies have generated several mouse lines with mutations in the DA system. Mice that lack either the Nurr1 12) or TH 13) gene or DA production 14) die at a late embryonic stage or shortly after birth, suggesting that DA is essential for embryonic development. In contrast, mice that lack D 2 -receptors show decreased spontaneous movement, as in drug-induced parkinsonism, 15) while mice that lack D 1 16) or D 3 -receptors 17) show increased locomotive activity. Thus, D 2 -receptor-deficient mouse may be a useful model for parkinsonism. However, it is unknown whether parkinsonism involves mutation(s) in the D 2 -receptor gene.
DA NEURONS AND THEIR VULNERABILITY
Brains of PD patients show evidence of impaired mitochondrial complex I 18) and the generation of oxidative stress. 19) Therefore, dysfunction of mitochondrial complex I and oxidative stress may be critical components of nigral DA neurodegeneration. 3, 4) Insight into the molecular mechanisms of DA neuronal death has come from studies using 6-hydroxydopamine (6-OHDA), 20) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 21, 22) and rotenone. 23) Based on these studies, it has been speculated that sporadic PD is caused by endogenous and environmental neurotoxins such as Nmethyl-(R)-salsolinol, N-methyl tetrahydroisoquinoline, bcarbolines or pesticides. However, the actual toxin, which is more neurotoxic than MPTP, has not yet been identified. 24) MPTP is converted by monoamine oxidase B (MAO-B) to 1-methyl-4-phenylpyridinium (MPP ϩ ), which is accumulated intracellularly in neurons via DA transporter (DAT). MPP ϩ , a potent inhibitor of mitochondrial complex I, like rotenone, 23) causes the production of reactive oxygen species (ROS), which induces apoptotic death in DA neurons. 25) Interestingly, MPTP causes death even in an invertebrate flatworm planarian, which is the most primitive species with a centralized nervous system, 26) suggesting that MPTP is a DA neurotoxin that is common to both invertebrates and primates. 27) The neurotoxicity of MPTP has also been examined in gene-mutant mice. Mice overexpressing human wild-type Cu/Zu-superoxide dismutase (SOD1) 28) and mice lacking neuronal NO synthase (nNOS) 29) are resistant to the neurotoxic effects of MPTP. Mice that lack inducible NO synthase (iNOS) are resistant to the MPTP-induced decrease in THpositive neurons, but show no change in DA-depletion. 30) In contrast, glutathione peroxidase (GSHPx)-homozygote deficient mice 31) and vesicular monoamine transporter 2 (VMAT2)-heterozygotes 32) show enhanced MPTP neurotoxicity. Thus, the vulnerability of DA neurons is influenced by enzymes that regulate oxidative stress.
a-SYNUCLEIN AND PARKIN IN THE PATHOLOGY OF PD
LBs and Lewy neurites are the defining neuropathological characteristics of PD and DLB. They are made of abnormal filamentous assemblies of full-length a-synuclein. 33 ) LBs contain predominantly a-synuclein, 33) but also ubiquitin, 34) UCH-L1, 35) cytochrome c, 36) synphilin-1, 37) parkin, 38) etc. aSynuclein in mammals is expressed abundantly in presynaptic terminals, but not specifically in DA neurons. [39] [40] [41] In several autosomal dominant PD families, two mutations in the amino-terminal region of a-synuclein have recently been identified, i.e., substitution of alanine at amino acid position 30 by proline (A30P) and at position 53 by threonine (A53T). 6, 7) Interestingly, mouse and rat carry the A53T allele as normal sequences in the a-synuclein protein, while A30 is the same as the human wild-type. The full-length of these wild-type and mutant a-synuclein proteins self-aggregate, and such aggregation is facilitated by cytochrome c, oxidative stress or synphilin-1. 36, 37) On the other hand, a fragment of a-synuclein (amino acid residues 61-95, an extremely hydrophobic region) has been considered to be a non-amyloid b component (NAC) in amyloid plaques in Alzheimer's disease brains. 42) Thus, a-synuclein may be implicated in the etiology of neurodegenerative disorders such as PD, DLB and Alzheimer's disease. 43) AR-JP patients, whose brains show a severe loss of DA neurons without LB, usually respond well to L-DOPA. 5, 8) AR-JP is caused by a loss of functional parkin. Since parkin has a ubiquitin-protein ligase (E3) activity and contributes to the degradation of unfolded proteins by proteasomes, [44] [45] [46] the accumulation of parkin substrates should lead to the degeneration of DA neurons. Recently, a synaptic vesicleassociated protein CDCrel-1, 46) glycosylated a-synuclein (aSp22) 47) and the parkin-associated endothelin receptor-like receptor (Pael-R) 48) have been shown to be parkin substrates. Among these, the overexpression of Pael-R in cultured cells induced endoplasmic reticulum (ER) stress and then caused cell death. 48) These observations suggest that dysfunction of a-synuclein and parkin may participate in the pathogenesis of PD, although further examinations are necessary.
ANTIPARKINSONIAN DRUGS AND BEHAVIORAL IMPROVEMENT
In humans, the pars compacta of the substantia nigra (SNc) contains approximately 450000 DA neurons. 1) In PD brains, since the number of nigrostriatal DA neurons decreases to less than 20%, the amount of DA in the striatum (caudate nucleus and putamen) is also markedly decreased. Therefore, motor dysfunction occurs in PD patients. DA, glutamate and acetylcholine (ACh) regulate g-aminobutyric acid (GABA) neurons in the striatum (Fig. 2) . Anticholinergic drugs such as trihexiphenidyl, etc. (Table 2 ) have a predominant effect on resting tremor and help relieve drooling, but have limited if any benefit for other signs and symptoms of PD. 49) On the other hand, although it was previously believed that the relative balance of DA and ACh in the striatum regulates motor activity, the detailed mechanisms of the function of ACh neurons in normal striatum and the effects of anticholinergics in PD patients are still unknown. Since adenosine regulates striatal GABA/enkephalin-containing neurons that project to the external segment of the globus pallidus (indirect pathway) (Fig. 2) , which have a predominant role in 286 Vol. 25, No. 3 PD, adenosine A 2A receptor antagonists may also be useful (Table 2) . On the other hand, the amount of noradrenaline in PD brains is also decreased. L-threo-DOPS is metabolized to noradrenaline by AADC ( Fig. 1 ) and improves the freezing symptom. Therefore, this drug is used as an adjunct to L-DOPA therapy. L-DOPA substitution is still considered the gold standard of antiparkinsonian drug therapy. However, motor response oscillations and drug-induced, abnormal involuntary movements develop in most PD patients who receive L-DOPA monotherapy for more than 5 years. L-DOPA and DA have been shown to be neurotoxic in vitro. 50, 51) While the chronic administration of L-DOPA is believed to participate in its side-effects, there is no clinical evidence to suggest that L-DOPA has adverse effects on DA neurons. 49, 51) Therefore, as part of an L-DOPA-sparing strategy, several agents have been developed, such as inhibitors of AADC, MAO-B and COMT, DA releasers and DA receptor agonists ( Table 2 ). New approaches have also recently been tried, such as monotherapy with DA receptor agonists and early therapy in combination with L-DOPA. 49, 51) 
NEUROPROTECTIVE EFFECTS IN IN VITRO AND IN VIVO MODELS
In vitro models usually involve the use of MPP ϩ , 6-OHDA or glutamate in primary cultures of rat or mouse mesencephalic neurons or DA-neuron-derived cell lines such as rat PC12, human neuroblastoma SH-SY5Y, etc. On the other hand, MPTP-treated monkey and C57BL/6 mouse have been used as in vivo model. 21, 22, 27) Previous studies have found that DA receptor agonists which are used for symptomatic PD therapy may have neuroprotective effects. 49, 52, 53) Therefore, the neuroprotective properties of antiparkinsonian drugs have recently been examined.
In in vitro studies, the death of cultured neuronal cells was inhibited by a MAO-B inhibitor (selegiline), 54) DA receptor agonists (bromocriptine, pramipexole, talipexole, etc.), 25, 55, 56) and glial cell line-derived neurotrophic factor (GDNF). 57) In in vivo studies, MPTP-induced striatal DA neurodegeneration in C57BL/6 mouse and monkey and brain damage in other models were also inhibited by selegiline (deprenyl), 58, 59) bromocriptine, 59, 60) pergolide, 58) pramipexole, 59, 61) talipexole, 59, 62) immunophilin ligands (GIP-1046, FK-506, cyclosporin A) 63, 64) and several neurotrophic factors (GDNF, neurotrophin-4/5, basic fibroblast growth factor, etc.). [65] [66] [67] [68] In contrast, epidemiological studies have indicated that the incidence and prevalence of PD tend to be lower in women than men, 69) and in cigarette-smokers compared to nonsmokers.
1) Therefore, female sex hormones and/or nicotine may also have neuroprotective effects. Thus, several antiparkinsonian drugs and reagents may have DA neuroprotective effects. However, their protective mechanisms vary (Table 2) , as described below.
ANTIOXIDANT PROPERTIES
Oxidative stress may be a component of nigral DA neurodegeneration in PD. 3, 4) Similar phenomena were observed in MPTP-treated animals used as models of parkinsonism. 27, 70) Recent studies have suggested that ergot-derivative D 2 -receptor agonists, such as bromocriptine, pergolide and cabergoline, directly scavenge hydroxyl and/or nitric oxide (NO) radicals [71] [72] [73] [74] and inhibit lipid peroxidation. 75, 76) Ropinirole, a non-ergot D 2 -receptor agonist, also scavenges free radicals and suppresses lipid peroxidation. 77) In addition, ropinirole increases the level of the endogenous antioxidant glutathione (GSH) and increases the expression of GSHPx, GSH reductase and GSH S-transferase. 78) In contrast, other non-ergot D 2 -receptor agonists, pramipexole and talipexole, inhibited MPP ϩ -induced ROS production, 25) although it is unknown whether these drugs directly scavenge ROS. These drugs may stabilize mitochondria directly by inhibiting transition pore opening 79) and/or indirectly through the expression of Bcl-2.
25) These antioxidant properties may participate in the neuroprotection of DA neurons.
INHIBITION OF a-SYNUCLEIN AGGREGATION AND LB FORMATION
Aggregated a-synuclein is markedly included in LBs in PD brains. Overexpression of human a-synuclein in mice 80) and Drosophila 81) caused the degeneration of DA neurons and motor dysfunction. In addition, the in vitro aggregation of a-synuclein was facilitated by ROS and cytochrome c. 36, 43) Therefore, the inhibition of a-synuclein aggregation and/or LB formation are possible of targets for antiparkinsonian drugs (Fig. 3) .
Interestingly, while pramipexole and talipexole (non-ergot D 2 -receptor agonists) inhibited the in vitro aggregation of asynuclein and cytochrome c, 82) they inhibited a-synuclein aggregation only at higher concentrations. Therefore, a usual clinical dose of pramipexole or talipexole can not be expected to inhibit a-synuclein aggregation. Specific inhibitors of a-synuclein aggregation that can contribute to inhibition of LB formation are needed in the near future.
INDUCTION OF ANTIAPOPTOTIC PROTEINS OR INHIBITION OF PROAPOPTOTIC ACTIVATION
The antiapoptotic Bcl-2 and Bcl-x proteins are well known to inhibit the release of apoptogenic cytochrome c from mitochondria into the cytosol.
83) The level of Bcl-2 protein is known to be up-regulated in brains of patients with PD 84) as well as those with Alzheimer's disease. 85) Such up-regulation of Bcl-2 protein may represent a compensatory response of remaining neurons to protect themselves from oxidative stress and subsequent apoptosis. Therefore, neurons with lower Bcl-2 expression may be more vulnerable to apoptotic death.
Pretreatment with pramipexole or talipexole, but not bromocriptine, for 4 d induced Bcl-2 expression and then inhibited MPP ϩ -induced apoptosis in human SH-SY5Y cells. 25) These drugs also inhibited the MPP ϩ -induced release of cytochrome c from mitochondria into the cytosol.
82) Estradiol 69) and nicotine 86) also induced Bcl-2 expression, and neurotrophic factor GDNF 57) induced the expression of both Bcl-2 and Bcl-x.
Apoptogenic cytochrome c, which is released from mitochondria into the cytosol, activates the intermediates Apaf-1 and caspase-9, and then activates caspase-3, which leads to apoptotic cell death (Fig. 3) . 83) The activation of caspase-3 may also participate in the vulnerability of DA neurons in PD. 87) At higher concentrations, pramipexole and talipexole inhibited the activation of caspase-9 and caspase-3 in similar manners and with similar potencies, suggesting that these drugs may also inhibit Apaf-1 at higher concentrations. 82) In addition, recent studies have suggested that ER stress-induced neurodegeneration may also play a role in the pathology of PD. 45, 47, 48) Therefore, drugs that inhibit the neuronal death induced by oxidative stress and/or ER stress should also be useful for treating parkinsonism.
NEURONAL SPROUTING AND REGENERATION
The allogeneic transplantation of human fetal mesencephalon is currently being studied, and initial reports show promising results. 2, 3) However, this strategy involves ethical issues and problems in obtaining adequate numbers of DA neurons (at least 3 to 4 fetuses may be required per side, or 6 or more fetuses per patient). Therefore, other approaches are being studied, such as the transplantation of neuronal stem cells or gene-transfected neuronal cells which differentiate to DA neurons, 2, 3) or the implantation of foreign cells which produce DA or GDNF, in semipermeable polymeric capsules. 88, 89) Antiapoptotic Bcl-2 protein also induces neuronal differentiation 90) and promotes the regeneration of severed axons in mammalian neurons. 91) Thus, Bcl-2 protein plays a role in both antiapoptosis and neuronal regeneration. In fact, transgenic mice expressing human Bcl-2 are resistant to MPTP neurotoxicity. 92) Repeated administration of pramipexole or talipexole markedly increased Bcl-2 protein neuronal dendritic processes in rats. 93) Similarly, the immunophilin ligand GPI-1046 elicited neurite outgrowth and induced regenerative sprouting from spared nigrostriatal DA neurons following treatment with MPTP and 6-OHDA. 64 ) Based on these observations, these drugs which induce neuronal sprouting and regeneration, like neurotrophic factors, may also use as antiparkinsonian drugs.
CONCLUSION
Recently, numerous factors and multiple pathways which regulate DA neuronal death and LB formation have been identified. Elucidating these mechanisms in detail will aid in the development of useful therapeutic strategies or treatments with which to combat PD and parkinsonism. Unfortunately, none of the currently available treatments have been proven to slow the progression of PD. Antiparkinsonian drugs have not yet been shown to have neuroprotective effects in human patients, although several drugs exhibit such effects in both in vitro and in vivo models. As new drugs become available, treatments that influence oxidative stress, ER stress, the progression of DA neurodegeneration and causative gene products may all be considered in attempts to achieve effective neuroprotection. The structural outline of the human genome was recently analyzed, and this should facilitate linkage analysis in human diseases. In the future, patients will be treated with a tailor-made therapy in PD and parkinsonism. Therefore, we hope that several different types of potent neuroprotective drugs, which delay the onset of disability that requires therapy with L-DOPA by slowing the progression of the disease, will be developed in the near future. In addition, several optional drugs for the neuroprotection of vulnerable DA neurons in PD and parkinsonism are also needed.
